Opens in a new tab or window SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Mounjaro and Zepbound. The medical news website Medscape first reported the warning label update on Wednesday. GLP-1s — which ...

Zepbound, at a fraction of the branded cost, but with little known about their efficacy or safety. Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because ...

But after gaining more than 20 pounds during undergraduate and graduate school and feeling unhappy with her weight, the ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

Drugs and weight loss often go hand in hand, but the journey can feel overwhelming—especially when your wallet takes a hit.

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite ...

Eli Lilly fell short of Wall Street sales estimates for its weight-loss and diabetes drugs on Wednesday, hit by a decrease in ...